Navigation Links
Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates
Date:12/22/2009

LONDON, ON, Dec. 22 /PRNewswire/ - Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384. These patents join a portfolio of more than 80 previously-granted patents for Viron's multiple therapeutic candidates. Viron's unique drug discovery platform identifies proteins expressed by non-human viruses that have evolved over millions of years of evolutionary selection to evade their host's immune system, endowing them with powerful immuno-modulatory and anti-inflammatory properties.

The new patent, US 7,514,405, entitled "Methods for treating transplant rejection," covers the treatment of chronic transplant rejection by administering VT-111 in combination with an immunosuppressant, such as cyclosporine. "This patent extends protection for VT-111 in transplant out to at least 2021," said Kevin Sullivan, Vice President of Business Development for Viron Therapeutics. "This provides ample time for us to unlock the commercial potential arising from upcoming organ transplant trials." Viron will pursue the transplant indication in parallel with Acute Coronary Syndromes (ACS) for VT-111, due to the significant unmet medical need in this space and the resulting rapid regulatory path forward. There are currently no therapeutic molecules targeting chronic organ rejection.

Viron's lead therapeutic candidate, VT-111, has demonstrated potent effects in preclinical suppression of chronic organ transplant rejection and, in a Phase IIa clinical trial of 48 patients, demonstrated reduced cardiac tissue damage in patients with ACS receiving cardiac stent implants. "It is remarkable to see such a small trial demonstrate such a strong, statistically significant impact in this target population," said Mr. Sullivan. "These trial results provide a compelling validation of Viron
'/>"/>

SOURCE Viron Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
2. Landfill mining reduces environmental impact of growing waste
3. Landfill mining reduces environmental impact of growing waste
4. Nanowire generates power by harvesting energy from the environment
5. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
6. Environmental Tectonics Corporations BioMedical Division Announces New Contract
7. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
8. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
9. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
10. Nanotechs health, environmental impacts worry scientists and the public
11. Fixed C-Arms Revolutionize Operating Room Environments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The Americas Inorganic Refrigerants Market report defines ... with analysis and forecast of revenue. , Browse ... Market report, to get an idea of the ... of the segmentation in the Americas inorganic refrigerants ... figures. , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html , Inorganic ...
(Date:10/22/2014)... 22, 2014 Currently offering a ... & D Weighing, Rice Lake, and Ohaus, Pipette.com ... . The Sartorius CPA Semi-Micro Balance is ideal ... precise, and user-friendly laboratory balance. , Sartorius is ... their laboratory balances are well known for their ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Calif., June 23, 2011 Nile Therapeutics, Inc. (OTCQB: ... heart failure patients, today announced that it has completed ... securities consisting of an aggregate of 5,000,000 shares of ... 2,500,000 shares of common stock for aggregate gross proceeds ...
... 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), ... HIV/AIDS vaccines, announced today the opening of a third ... vaccine.  The Los Angeles-based AIDS Research Alliance (ARA) will ... site team: the AIDS Research Consortium of Atlanta and ...
... NEW YORK, June 22, 2011 Veredus Laboratories, a ... partner, STMicroelectronics (NYSE: STM ), today announced ... application that is able to detect 10 to 12 ... Escherichia coli (E. coli) responsible for the ...
Cached Biology Technology:Nile Therapeutics, Inc. Completes $2.5 Million Private Placement 2Nile Therapeutics, Inc. Completes $2.5 Million Private Placement 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 4Veredus Laboratories Develops Lab-on-Chip Solution to Detect and Differentiate Several Food-Borne Pathogens, Including Escherichia coli (E. coli) 2Veredus Laboratories Develops Lab-on-Chip Solution to Detect and Differentiate Several Food-Borne Pathogens, Including Escherichia coli (E. coli) 3Veredus Laboratories Develops Lab-on-Chip Solution to Detect and Differentiate Several Food-Borne Pathogens, Including Escherichia coli (E. coli) 4
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... in female mice to an enzyme activated by the ... resistant to respiratory infections than males. Now, an international ... bacterial pneumonia in female mice is linked to the ... that this enzyme is ultimately activated by the release ... lead by Professor Lester Kobzik at the Harvard University ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3New book about life as seen from physics 2
... from L-1 and Terminates Discussions ... ... ("L-1") (NYSE: ID ), a leading provider of identity solutions ... with Digimarc Corporation ("Digimarc") (Nasdaq: DMRC ). The,proposed transaction values ...
... Calif., June 30, 2008--In a breakthrough scientific study published ... of Sciences , scientists at the Burnham Institute for ... may be linked to Autism. The study demonstrated that ... in neural stem cells had smaller brains, fewer nerve ...
... College of Medicine and her colleagues discovered the first ... the intestines, causing diarrhea. The next step ... through which the enterotoxin interacts to cause diarrhea. ... be straightforward," said the professor of molecular virology and ...
Cached Biology News:Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 2Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 3Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 4Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 5Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 6Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 7Researchers link early stem cell mutation to autism 2Integrins as receptors give insight into rotavirus and diarrhea 2
Request Info...
Loading Buffer...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Request Info...
Biology Products: